The drugs are there. The question now is how to get them to people.
Only 48% of metastatic lung cancer patients receive chemotherapy, immunotherapy, or targeted therapy despite significant advances in treatment options. Late-stage diagnosis is a primary barrier; lung cancer often goes undetected until metastasis due to lack of symptoms and underutilized screening programs.
- Only 48% of metastatic lung cancer patients receive life-extending treatments
- Over 110,000 Americans diagnosed annually with metastatic lung cancer
- Study analyzed 250,000+ Medicare patients between 2006 and 2021
- Lung cancer often goes undetected until metastasis due to lack of symptoms
Over 50% of Medicare patients with metastatic lung cancer forgo life-extending treatments despite breakthrough drugs, with barriers including late diagnosis, access issues, and patient hesitancy.
The drugs exist now. They work. A single pill can hold metastatic lung cancer at bay for years—a transformation that would have seemed miraculous a decade ago. Yet more than half of the patients who need them never receive them.
A study published this week in JAMA Oncology examined the medical records of over 250,000 Medicare patients treated between 2006 and 2021, with an average age of 73. The finding was stark: only 48 percent received chemotherapy, immunotherapy, or targeted therapy. That proportion had barely budged over fifteen years, creeping up from 45 percent. In a field where breakthrough treatments arrive regularly, where the science has fundamentally shifted what's possible, the treatment gap remains stubbornly wide.
Lung cancer kills more Americans than any other malignancy. Each year, more than 110,000 people receive a diagnosis of metastatic disease—cancer that has already spread beyond the lungs. The disease was once a near-certain death sentence. Now, for many patients, it can become something closer to a chronic condition, manageable with the right intervention. Dr. Carolyn J. Presley, chief of thoracic medical oncology at Ohio State University, put it plainly: the fact that so many older adults are not getting treatment is "really, really sobering."
The barriers, experts say, are layered and interconnected. One of the most fundamental is diagnosis itself. The lungs contain almost no pain receptors. Tumors can grow silently for months or years, causing no symptoms at all. By the time a patient feels something wrong—a persistent cough, chest pain, shortness of breath—the cancer has often already metastasized. Screening programs exist that could catch tumors earlier, but they remain vastly underutilized. Most people don't know screening is available. The eligibility criteria are complicated enough that many doctors struggle to determine who qualifies.
Even when a suspicious finding appears on a scan, the path to treatment becomes a gauntlet of delays. Follow-up imaging takes time. A biopsy must be scheduled. Appointments with specialists stretch out. Dr. Kyle Concannon, a thoracic medical oncologist at the University of Colorado Anschutz, noted that patients can lose weeks or months in this waiting period—time the cancer uses to advance further. The study itself couldn't identify all the reasons patients decline or never receive treatment. But researchers point to a constellation of factors: shame around a disease still widely associated with smoking, even though many patients never smoked; practical access barriers like transportation and insurance coverage; and a kind of fatalism, a belief that treatment won't help or that the disease is simply too far gone.
The gap between what medicine can now do and what patients actually receive is not a failure of science. It's a failure of systems—of screening infrastructure, of patient education, of the thousand small frictions that keep people from the care that could extend their lives. The drugs are there. The question now is how to get them to the people who need them.
Notable Quotes
The fact that so many older adults are not getting treatment is really, really sobering.— Dr. Carolyn J. Presley, chief of thoracic medical oncology at Ohio State University
The Hearth Conversation Another angle on the story
Why does a disease with such effective new treatments still go untreated in half of patients?
Because the disease itself is invisible. Lung cancer doesn't announce itself. By the time someone feels sick, it's often too late to catch it early, and the window for treatment has narrowed.
But the study looked at people who were already diagnosed. They knew they had metastatic lung cancer. So why didn't they get treatment?
That's the harder question. Some of it is practical—getting to appointments, affording care, navigating insurance. But some of it is psychological. There's still deep shame attached to lung cancer, even though many patients never smoked. And there's fatalism. If you're 75 and you hear you have stage 4 cancer, it's easy to believe nothing will help.
The article mentions that screening is underutilized. Is that because it's not available, or because people don't know about it?
Both. The screening exists, but most people have never heard of it. And the eligibility rules are so tangled that even doctors can't always figure out who qualifies. So the disease gets diagnosed late, when it's already spread.
If someone does get diagnosed early enough, what's the treatment like?
It depends on the type of cancer and the patient's genetics. Some people take a pill daily that keeps the cancer in check for years. Others need chemotherapy or immunotherapy. The point is, these aren't experimental anymore. They work. But you have to get to them before the disease has progressed too far.
So the real problem is time.
Time and access. The cancer doesn't wait. Neither does the bureaucracy. And patients caught in between often give up before they ever reach treatment.